← All companies
10x Genomics, Inc.
TXG - CIK 0001770787
Market cap$3.72 B
Rank#1634
SEC filings652
10x Genomics, Inc. trades as TXG and has a market capitalization of $3.72 B, making it the #1634 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $642.82M, up 5.2% from the prior year and net income of -$43.50M. This page tracks 10x Genomics, Inc. through 652 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$642.82MFY 2025
Net income (latest FY)-$43.50MFY 2025
Operating cash flow (latest FY)$136.05MFY 2025
Total assets (latest FY)$1.04BFY 2025
Gross margin69.1%latest FY
Net margin-6.8%latest FY
Financial performance
Over the last 8 fiscal years 10x Genomics, Inc.'s revenue grew from $71.08M to $642.82M, a compound annual growth rate of 31.7%. Net profit margin expanded from -26.4% to -6.8% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $3.72 B
- Share price (derived)market cap / shares outstanding
- $29.11
- EPS (diluted)FY 2025
- $-0.35
- Shares outstandingas of 2025-12-31
- 0.13B
- Total equityas of 2026-03-31
- $814.32M
- Return on equity
- -5.3%
- Cash & equivalentsas of 2024-12-31
- $344.07M
- Stock buybacksFY 2017
- $80.00K
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-22 |
| Quarterly report | 10-Q | 2026-05-08 |
| Major company event | 8-K | 2026-05-07 |
| SCHEDULE 13G | - | 2026-04-29 |
| SCHEDULE 13G | - | 2026-04-28 |
Recent press releases
- 10x Genomics Reports First Quarter 2026 Financial Results2026-05-07
PLEASANTON, Calif. , May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG ), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.
- 10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference2026-04-29
PLEASANTON, Calif. , April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG ), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m. Pacific Time.
- 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 20262026-02-12
PLEASANTON, Calif. , Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG ), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026.
Similar companies
The largest companies sharing 10x Genomics, Inc.'s SEC industry classification (laboratory analytical instruments).
Frequently asked questions
What is 10x Genomics, Inc.'s market cap?
10x Genomics, Inc. (TXG) has a market capitalization of $3.72 B as of 2026-06-10, ranking #1634 among US-listed companies.
How much revenue does 10x Genomics, Inc. make?
10x Genomics, Inc. reported revenue of $642.82M for fiscal year 2025, an increase of 5.2% year over year.
Is 10x Genomics, Inc. profitable?
In its latest fiscal year 10x Genomics, Inc. reported a net loss of $43.50M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.